Drug screening approach combines epigenetic sensitization with immunochemotherapy in cancer.

ABSTRACT: BACKGROUND:The epigenome plays a key role in cancer heterogeneity and drug resistance. Hence, a number of epigenetic inhibitors have been developed and tested in cancers. The major focus of most studies so far has been on the cytotoxic effect of these compounds, and only few have investigated the ability to revert the resistant phenotype in cancer cells. Hence, there is a need for a systematic methodology to unravel the mechanisms behind epigenetic sensitization. RESULTS:We have developed a high-throughput protocol to screen non-simultaneous drug combinations, and used it to investigate the reprogramming potential of epigenetic inhibitors. We demonstrated the effectiveness of our protocol by screening 60 epigenetic compounds on diffuse large B-cell lymphoma (DLBCL) cells. We identified sev

SUBMITTER: Facciotto C 

PROVIDER: S-EPMC6907220 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature